Highest-materiality recent filing
Q2 total revenues $234.3M (+66% YoY); adjusted net income $30.9M (+134% YoY); GAAP net loss $180.2M due to $191.3M non-cash impairment on NARCAN asset group.
Emergent BioSolutions secures $52.7M contract modification from ASPR for ACAM2000 supply
$52.7M modification exercises Option Year 7 under existing 10-year ASPR contract.
Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA
Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).
New $150M Term Loan with OrbiMed matures April 2031, replaces prior $150M OHA facility; ABL reduced to $50M.
EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M
Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.
Emergent BioSolutions voluntarily prepays $100M of term loan; total debt reduced by $275M since 2023
Voluntary prepayment of $100M on term loan using cash on hand in late December 2025.
Emergent BioSolutions receives FDA approval for raxibacumab manufacturing at Winnipeg site
FDA approved sBLA for Winnipeg as drug product manufacturing and testing site for raxibacumab.
Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view
Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).
Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M
Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.
Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine
Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
Emergent BioSolutions Q2 revenue $140.9M, beats guidance; raises FY profitability outlook
Q2 revenue $140.9M (above Q2 guidance by $21M); net loss improved to $12.0M from $283.1M loss a year ago.
Emergent BioSolutions secures $62.4M contract modification from ASPR for botulism antitoxin BAT
Modification and option exercise valued at $62.4 million under existing 10-year ASPR contract (75A50119C00075).
Court grants preliminary approval of $15M derivative suit settlement; final hearing Aug 6
Settlement covers five derivative actions alleging breach of fiduciary duty over Bayview vaccine manufacturing failures.
Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M
Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.
Emergent closes sale of Baltimore-Bayview facility to Syngene for ~$36.5M
Sale closed on March 19, 2025; Emergent received ~$36.5M at closing, subject to post-closing adjustments.
Emergent BioSolutions sells Baltimore-Bayview manufacturing site to Syngene for $36.5M
Sale of Bayview drug substance manufacturing facility to Syngene Intl for ~$36.5M; closing expected Q1 2025.
Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.
Emergent gains exclusive U.S./Canada commercial rights to Hikma's KLOXXADO 8 mg naloxone spray
Six-year agreement gives Emergent exclusive rights to market and distribute KLOXXADO (naloxone HCl) 8 mg nasal spray in U.S. and Canada.
Emergent receives $50M BARDA CYFENDUS option and $20M DoD BioThrax option
BARDA awarded $50M option for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted); deliveries through April 2025.
Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance
Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.
Emergent BioSolutions closes $100M ABL credit facility, reports $150M cash balance
New asset-based revolving loan facility of up to $100M, maturing September 2029.
Emergent BioSolutions closes $250M term loan with Oak Hill Advisors; extends maturity to 2029
$250M term loan drawn in full, matures August 2029; used to repay existing senior term loan due May 2025 and terminate revolver.
Emergent BioSolutions gets FDA approval for ACAM2000 mpox indication
FDA approved sBLA for ACAM2000 to prevent mpox in high-risk individuals based on animal study safety/efficacy data.
Emergent BioSolutions Q2 revenue $254.7M, net loss $283.1M; updates FY2024 guidance
Q2 revenue $254.7M (above guidance); net loss $283.1M ($5.38/diluted), adjusted EBITDA -$10.1M.
Emergent BioSolutions sells RSDL decontamination kit to SERB for $75M
Cash purchase price of $75M at closing; additional $5M milestone payment for component sourcing.
Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M
Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.
Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds
Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.
Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M
Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.
Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.
Emergent BioSolutions to cut ~300 jobs, close two facilities, targeting $80M annual savings
Reduces workforce by ~300 employees and eliminates ~85 vacant positions across all areas.
Emergent Q1 rev $300M, net income $9M; raises FY2024 adj EBITDA guidance to $125-175M
Q1 2024 total revenues $300.4M (up 83% YoY), net income $9.0M vs loss of $186.2M last year.
Emergent BioSolutions amends credit facility; revolver cut to $270M, interest margins raised
Revolving commitments reduce to $270M through July 30, then $225M, and $200M after Oct 31, 2024.
Emergent BioSolutions awards $1.45M in additional retention bonuses to four top executives
CFO Richard Lindahl receives $399,753; GC Jennifer Fox $380,250; EVP Quality Coleen Glessner $373,761; SVP Products Paul Williams $292,501.
Emergent posts Q4 loss of $50M, FY loss of $760.5M; secures lender forbearance until April 30
Q4 2023 total revenues $277M, down 16% YoY; net loss $49.5M ($0.95 diluted loss); adjusted EBITDA $3M.
Joseph C. Papa appointed President and CEO effective Feb 21, 2024; succeeds interim CEO Haywood Miller.
On October 16, 2026, Emergent BioSolutions Inc. (the “ Company ”) announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.
The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027.
Emergent BioSolutions, Inc. (the “Company”) announced that Jennifer Fox is resigning as Executive Vice President External Affairs, General Counsel and Corporate Secretary of the Company to pursue an opportunity outside of the Company and will continue in her current role until August 16, 2024.
appointed Joseph C. Papa as President and CEO of the Company, effective February 21, 2024.
Mr. Papa has been appointed as Class II director of the Board
Haywood Miller, who will step down from his role as interim CEO of the Company, effective February 21, 2024.
On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023
On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023
On August 16, 2023, Emergent BioSolutions Inc. (the “Company”), announced that Jerome Hauer, Ph.D., a director of the Company, had passed away on Friday August 11, 2023.
The Company also announced that Bill Hartzel, Senior Vice President and head of bioservices, will assume responsibility for manufacturing operations and will join the Executive Management Team, reporting to the interim CEO, Haywood Miller.
As such, Adam Havey, Executive Vice President and current COO, will be leaving the Company effective September 30, 2023.
On June 24, 2023, the Board appointed Haywood Miller of Berkeley Research Group to serve as a non-employee interim Chief Executive Officer, effective immediately, until the Board’s search for a permanent Chief Executive Officer is completed.
Max materiality 0.90 · Median 0.65 · Most common event other_material